DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the NEPHRO CARE INDIA LIMITED (NEPHROCARE) share price today?

NEPHRO CARE INDIA LIMITED (NEPHROCARE) is trading at ₹65.45 on the NSE, up 0.77% on the day. Source: DocStoX.

What is the PE ratio of NEPHRO CARE INDIA LIMITED?

NEPHRO CARE INDIA LIMITED has a price-to-earnings (PE) ratio of 29.6 in the Healthcare Services sector.

What is the market capitalisation of NEPHRO CARE INDIA LIMITED?

NEPHRO CARE INDIA LIMITED has a market capitalisation of approximately ₹116 crore.

NEPHRO CARE INDIA LIMITED

NEPHROCARE·NSE·Healthcare Services

₹65.45▲ +0.50 (+0.77%)

Healthcare Services · Hospitals

Revenue compounding 73% a year

Day₹64.95

₹65.70

52W₹50

₹18312%

Open

₹64.95

High

₹65.70

Low

₹64.95

Prev Close

₹64.95

Volume

2.0K

VWAP

₹65.35

Snapshot

Key fundamentals

Market Cap

₹116 Cr

P/E Ratio

29.62Fair

P/B Ratio

2.04

EPS

₹2.21

Book Value

₹34.49

ROE

6.11%Weak

ROCE

11.27%Decent

Dividend Yield

0.00%

Debt / Equity

0.00Low

Face Value

₹10.00

52W High

₹183.00

52W Low

₹50.05

Sector

Healthcare Services

Industry

Hospitals

Avoid

None moatMedium uncertainty

Fair value estimate

₹34

▼ 48.5%downside

Trading at ₹65 — 48% above our estimate

BearFair valueBull

₹29₹34₹40

/100

Business quality — Watch the fundamentals

Growth 75Profitability 19Efficiency 8Valuation 75

Plain English

Our view

Revenue compounding 73% a year
Virtually debt-free balance sheet
Weak returns on equity (6%)

Strengths

Virtually debt-free balance sheet
Revenue compounding 73% over 3 years
Promoters hold a controlling stake

Risks

Weak returns on equity (6%)
Fundamental red flags (Piotroski 2/9)

How we got there

Fair value methods

Residual income

7% ROE fading to 12% over ~3 yrs, on ₹34 book

₹32

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹40

Analyst target

No analyst coverage

—

Blended fair value₹34

What the numbers say

Investment thesis

Bull case

Virtually debt-free balance sheet
Revenue compounding 73% over 3 years
Promoters hold a controlling stake

Bear case

Weak returns on equity (6%)
Fundamental red flags (Piotroski 2/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

29.6Fair

Below 15× is value territory; above 35× prices in strong growth

ROE

6.1%Weak

Above 15% is considered healthy for Indian equities

ROCE

11.3%Decent

Above 18% means capital is working hard

Debt/Eq

0.00Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹116 Cr

P/B

2.04

EPS

₹2.21

Div Yield

—

What changed

Recent changes

Foreign investors+0.7% stake last quarter
Domestic institutions+1.3% stake last quarter
Promoters+0.24% stake last quarter

What matters

News impact

Overview

Valuation

Reasonable

P/E 29.6×

Growth

Strong

+73% rev CAGR

Profitability

Modest

6.1% ROE

Financial health

Rock solid

D/E 0.00

Momentum

N/A

No technicals

Today

Trading activity

Delivery %100.0%

Turnover₹1.31L Cr

Trades5

VWAP₹65.35

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+73.2%

+117.6%

10Y

—

Profit

+10.6%

+104.4%

10Y

—

EPS

-65.0%

-53.1%

10Y

—

Profile

Pros

Company is almost debt free.

Watch-outs

Cons

Though the company is reporting repeated profits, it is not paying out dividend
Company has a low return on equity of 10.7% over last 3 years.

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Promoters raised their stake by 0.24 pts; foreign investors bought 0.73 pts; domestic institutions added 1.30 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

62%

Promoter

Promoters

61.7%+0.24

Public

30.3%+2.66

FII / FPI

0.7%+0.73

DII

1.3%+1.30

Others

5.9%

Total shareholders

1,845+201 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter61.71%

FII0.73%

DII1.30%

Public30.32%

Others5.94%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 2014, Nephro Care India Ltd is a healthcare provider that specializes in the treatment of kidney- related diseases[1]